Format

Send to

Choose Destination
J Peripher Nerv Syst. 2009 Mar;14(1):1-13. doi: 10.1111/j.1529-8027.2009.00200.x.

Prevalence of diabetic peripheral neuropathy and relation to glycemic control therapies at baseline in the BARI 2D cohort.

Collaborators (428)

Detre KM, Kelsey SF, Brooks MM, Kelley D, Orchard TJ, Rana J, Thomas SB, Tyrrell KS, Holubkov R, Averbach F, Crow SW, MacGregor JM, O'Neal SM, Pitluga K, Sansing V, Tranchine M, Hardison R, Kip K, Lu J, Lombardero M, Janiszewski S, Protivnak D, Reiser S, Barton S, Kushner Y, Michael O, Martin JP, Kania C, Kania M, O'Donnell J, Maxwell RA, Frye RA, Goldberg S, Rosenberg Y, Desvigne-Nickens P, Ershow A, Gordon D, Paltoo D, Jones TL, Hueb W, Ramires J, Lopes N, Wajchenberg B, Martinez EE, Oliveira SA, Betti R, Schwartz L, Steiner G, Barolet A, Groenewoud Y, Camelon K, Mighton L, O'Rourke R, Blodgett J, Sako E, Nicastro J, Prescott R, Rihal C, Kennedy F, Barsness G, Basu A, Clavell A, Frye R, Holmes DR Jr, Lerman A, Mullaney C, Reeder G, Rizza R, Schaff H, Smith S, Somers V, Sundt T, Ting H, Wright RS, Helgemoe P, Lesmeister D, Rolbiecki D, Lepe-Montoya L, Escobedo J, Barraza R, Baleón R, Campos A, García P, Lezama C, Miramontes C, Ocampo S, Peñafiel JV, Valdespino A, Verdín R, Albarrán H, Ayala F, Chávez E, Murillo H, Buitrón LV, Rico-Verdin B, Adler D, Halle AA, Ismail-Beigi F, Paranjape S, Mazzurco S, Ridley K, Ramanathan K, Solomon S, Weinman D, Wall B, Douglas L, Touchstone T, Bourassa M, Tardif JC, Chiasson JL, Lavoie MA, Langelier H, Foucher S, Trudel J, Monrad S, Srinivas V, Zonszein J, Crandall J, Duffy H, Vartolomei E, King S 3rd, Jacobs C, Robertson D, LaCorte J, Mock M, Porter M, Rogers W, Ovalle F, Bell D, Misra VK, Hillegass WB, Aqel R, Pierce P, Smith M, Saag L, Vaughn A, Smith D, Grimes T, Rolli S, Hill R, Barrett BD, Morehead C, Doss K, Davidson CJ, Molitch M, Beohar N, Goodreau L, Massaro E, Arroyo F, Pavlickova L, Neuzil P, Stehlíková S, Benedik J, Coling L, Davies R, Glover C, LeMay M, Mesana T, Ooi TC, Silverman M, Sorisky A, Favreau C, McClinton S, Weiss M, Weiss I, Saulle L, Kannam H, Kurylas JC, Vasi L, Douglas J Jr, Ghazzal Z, Sperling L, King S 3rd, Dayamani P, Gebhart S, Basu S, Helmy T, Tangpricha V, Hyde P, Jenkins M, Kent K, Suddath W, Magee M, Julien-Williams P, Reed V, Nassar C, Dagenais G, Garceau C, Auger D, Buller C, Elliott T, Ramanathan K, Fox R, Kolesniak D, Attubato M, Feit F, Richardson S, Pena-Singh I, Slater J, Amendola A, Vargas B, Gray SC, Regan D, Tsapatsaris N, Woods B, Cushing G, Rutter M, Singh P, DesRochers G, Woodhead G, Gannon D, Campbell NS, Ragosta M, Sarembock I, Barrett E, Powers E, Jahn L, Murie K, Das G, Sigurdsson G, White C, Bantle J, Redmon JB, Kwong C, Tamis-Holland J, Albu J, Hochman JS, Slater J, Wilentz J, Frances S, Tormey D, Pepine C, Smith K, Kennedy L, Brezner K, Curry T, Bleyer F, Albert S, Mooradian A, Plummer S, Fuentes F, Robles R, Lavis V, Gomez J, Underwood C, Fulton MS, Ramirez JG, Merta J, Scott G, Krishnaswami A, Dowdell L, Berkheimer S, Greenbaum A, Whitehouse F, Pangilinan R, Mann K, Jacobs A, Sternthal E, Ebner S, Beardsley P, Schneider D, Pratley R, Cefalu W, Schnure J, Rowen M, Tilton L, Niederman A, Mata C, Kellerman T, Farmer J, Garber A, Kleiman N, Howard N, Nichols D, Pool M, Granger C, Feinglos M, Adams G, Green J, Druken B, Underwood D, Stafford JL, Donner T, Laskey W, Beach D, Lopez J, Davis A, Faxon D, Reutrakul S, Bayer E, Marroquin O, Cohen H, Korytkowski M, Koerbel G, Baxendell L, Rosenfelder D, DeRiso L, Farrell C, Vita T, Bach R, Krone R, Makan M, McGill J, Recklein C, Luepke KM, Clifton MJ, Farkouh M, Kim M, Smith DA, Guzman I, Travis A, O'Keefe J, Forker A, Isley W, Moe R, Kennedy P, Rosson M, Long A, Bates E, Herman W, Pop-Busui R, Duvernoy C, Stevens M, Luciano A, Majors C, Gottlieb SH, Rodriguez A, Herr M, Williams D, Smith RJ, Abbott JD, Laufgraben MJ, Grogan M, Muratori J, Habib G, Marcelli M, Mikati I, Cordero E, Caldwell G, Schechter D, Lorber D, August P, Brown M, Depree P, Huber K, Hanusch-Enserer U, Jordanova N, Cilesiz D, Vogel B, McCallister B Jr, Mandagere K, Kleerekoper M, Urbanic R, Bengston J, Kong BK, Pruitt A, Sanfield J, Carulli C, Churley-Strom R, Magorien R, Osei K, Boyer CC, Lee R, Palumbo P, Roston S, Wisbey J, Alderman E, Ikeno F, Schwarzkopf A, Steffes M, Nowicki M, Bucksa J, Chaitman B, Eckstein J, Bertram T, Hlatky MA, Boothroyd DB, Melsop KA, Sobel BE, Rowen M, Neimane D, Iskandrian AE, Schaaf MB, Genuth S, Bongarno T, Nesto R, August P, Hultberg K, Gottlieb SH, Albu J, Rosenhouse-Romeo H, Orchard TJ, Pambianco G, Lombardero M, Mock M, Canton N, Frye RL, Brooks MM, Desvigne-Nickens P, Ershow A, Genuth S, Goldberg S, Gordon D, Hardison R, Jones TL, Kelsey S, Nesto R, Orchard T, Paltoo D, Rosenberg Y, Ryan T, Lebovitz H, Brown R, Friesinger G, Horton E, Mason J, Virmani R, Wechsler L, Bairey-Merz CN, Kennedy JW, Gordon D, Antman E, Colwell J, Fowler S, Furberg C, Goldman L, Jennings B, Rankin S.

Author information

1
Division of Metabolism, Endocrinology and Diabetes, Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109, USA. rpbusui@umich.edu

Abstract

We evaluated the associations between glycemic therapies and prevalence of diabetic peripheral neuropathy (DPN) at baseline among participants in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial on medical and revascularization therapies for coronary artery disease (CAD) and on insulin-sensitizing vs. insulin-providing treatments for diabetes. A total of 2,368 patients with type 2 diabetes and CAD was evaluated. DPN was defined as clinical examination score >2 using the Michigan Neuropathy Screening Instrument (MNSI). DPN odds ratios across different groups of glycemic therapy were evaluated by multiple logistic regression adjusted for multiple covariates including age, sex, hemoglobin A1c (HbA1c), and diabetes duration. Fifty-one percent of BARI 2D subjects with valid baseline characteristics and MNSI scores had DPN. After adjusting for all variables, use of insulin was significantly associated with DPN (OR = 1.57, 95% CI: 1.15-2.13). Patients on sulfonylurea (SU) or combination of SU/metformin (Met)/thiazolidinediones (TZD) had marginally higher rates of DPN than the Met/TZD group. This cross-sectional study in a cohort of patients with type 2 diabetes and CAD showed association of insulin use with higher DPN prevalence, independent of disease duration, glycemic control, and other characteristics. The causality between a glycemic control strategy and DPN cannot be evaluated in this cross-sectional study, but continued assessment of DPN and randomized therapies in BARI 2D trial may provide further explanations on the development of DPN.

TRIAL REGISTRATION:

ClinicalTrials.gov NCT00006305.

PMID:
19335534
PMCID:
PMC2692660
DOI:
10.1111/j.1529-8027.2009.00200.x
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Wiley Icon for PubMed Central
Loading ...
Support Center